1. Home
  2. UDMY vs DRUG Comparison

UDMY vs DRUG Comparison

Compare UDMY & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Udemy Inc.

UDMY

Udemy Inc.

N/A

Current Price

$4.71

Market Cap

1.0B

Sector

Real Estate

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$86.17

Market Cap

856.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UDMY
DRUG
Founded
2009
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
856.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
UDMY
DRUG
Price
$4.71
$86.17
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$9.00
$114.00
AVG Volume (30 Days)
2.1M
88.2K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
105.36
N/A
EPS
0.03
N/A
Revenue
$789,844,000.00
N/A
Revenue This Year
$4.44
N/A
Revenue Next Year
$6.02
N/A
P/E Ratio
$155.00
N/A
Revenue Growth
0.42
N/A
52 Week Low
$4.35
$23.18
52 Week High
$10.26
$123.75

Technical Indicators

Market Signals
Indicator
UDMY
DRUG
Relative Strength Index (RSI) 44.86 55.52
Support Level $4.35 $72.06
Resistance Level $5.06 $97.75
Average True Range (ATR) 0.27 5.56
MACD 0.03 1.05
Stochastic Oscillator 59.57 85.48

Price Performance

Historical Comparison
UDMY
DRUG

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: